AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
OREIOS International Study
Completed
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1127
- Registration Number
- NCT05239507
- Locations
- 🇦🇪
Research Site, Abu Dhabi, United Arab Emirates
A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT05236543
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Safety Study of AZD4041 in Healthy Participants
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT05233085
- Locations
- 🇨🇦
Research Site, Laval, Quebec, Canada
Epidemiology of Thrombotic Thrombocytopenia Syndrome in Integrated Health-care Database in England
Completed
- Conditions
- COVID-19
- Interventions
- Other: Pre-COVID-19Other: COVID-19 vaccination roll-outOther: COVID-19
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41200246
- Registration Number
- NCT05222750
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 999
- Registration Number
- NCT05221840
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 106
- Registration Number
- NCT05219630
- Locations
- 🇯🇵
Research Site, Osaka, Japan
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1
Active, not recruiting
- Conditions
- Relapsed or Refractory Classical Hodgkin Lymphoma
- Interventions
- Drug: Sabestomig (AZD7789)
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT05216835
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).
Phase 4
Completed
- Conditions
- Advanced NSCLC
- Interventions
- Genetic: Gene Profile explore
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 182
- Registration Number
- NCT05219162
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5
- Registration Number
- NCT05215951
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
REported Outcomes in COPD With Trixeo in Real worlD
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 148
- Registration Number
- NCT05213611
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath